APA (7th ed.) Citation

J, B., PA, F., FJ, C., S, D., I, L., J, O., . . . KA, G. (2024). Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: Final analysis of LUCY. Breast cancer research and treatment, 204(2), 237. https://doi.org/10.1007/s10549-023-07165-x

Chicago Style (17th ed.) Citation

J, Balmaña, et al. "Clinical Effectiveness and Safety of Olaparib in BRCA-mutated, HER2-negative Metastatic Breast Cancer in a Real-world Setting: Final Analysis of LUCY." Breast Cancer Research and Treatment 204, no. 2 (2024): 237. https://doi.org/10.1007/s10549-023-07165-x.

MLA (9th ed.) Citation

J, Balmaña, et al. "Clinical Effectiveness and Safety of Olaparib in BRCA-mutated, HER2-negative Metastatic Breast Cancer in a Real-world Setting: Final Analysis of LUCY." Breast Cancer Research and Treatment, vol. 204, no. 2, 2024, p. 237, https://doi.org/10.1007/s10549-023-07165-x.